Neurocognitive profile of a cohort of SMA type 1 pediatric patients and emotional aspects, resilience and coping strategies of their caregivers. (March 2023)
- Record Type:
- Journal Article
- Title:
- Neurocognitive profile of a cohort of SMA type 1 pediatric patients and emotional aspects, resilience and coping strategies of their caregivers. (March 2023)
- Main Title:
- Neurocognitive profile of a cohort of SMA type 1 pediatric patients and emotional aspects, resilience and coping strategies of their caregivers
- Authors:
- Tosi, Michele
Cumbo, Francesca
Catteruccia, Michela
Carlesi, Adelina
Mizzoni, Irene
De Luca, Giacomo
Cherchi, Claudio
Cutrera, Renato
Bertini, Enrico
D'Amico, Adele - Abstract:
- Abstract: Spinal muscular atrophy (SMA) type 1 represents the most severe condition of the spectrum of SMA 5q. In the absence of therapeutic interventions, patients do not achieve any motor milestone and their life expectancy does not exceed two years of age. To date, three disease-modifying drugs have been approved for SMA type I. These treatments have radically changed the natural history of the disease, improving motor, respiratory and bulbar functions. In recent years huge amount of data have been collected worldwide related to motor, respiratory and swallowing function outcome in treated patients, whereas the neurocognitive profile of treated patients has been poorly explored. Here we report the neurocognitive development profile of a cohort of SMA type I children treated with a disease modifying therapy. We also describe the burden and resilience as well as the coping strategies of their caregivers. Our finding show a global developmental delay in most patients and defects in gross motor functions contribute most to lower the general development quotient of Griffiths III, whereas the scores obtained on evaluating learning and language abilities scales suggest a positive trend in the developmental trajectory of general neurocognitive abilities. Some parents reported anxiety and stress but overall they were resilient (and had good coping strategies towards the burden of care for their child. These results reinforce the importance of routinely assessing the neurocognitiveAbstract: Spinal muscular atrophy (SMA) type 1 represents the most severe condition of the spectrum of SMA 5q. In the absence of therapeutic interventions, patients do not achieve any motor milestone and their life expectancy does not exceed two years of age. To date, three disease-modifying drugs have been approved for SMA type I. These treatments have radically changed the natural history of the disease, improving motor, respiratory and bulbar functions. In recent years huge amount of data have been collected worldwide related to motor, respiratory and swallowing function outcome in treated patients, whereas the neurocognitive profile of treated patients has been poorly explored. Here we report the neurocognitive development profile of a cohort of SMA type I children treated with a disease modifying therapy. We also describe the burden and resilience as well as the coping strategies of their caregivers. Our finding show a global developmental delay in most patients and defects in gross motor functions contribute most to lower the general development quotient of Griffiths III, whereas the scores obtained on evaluating learning and language abilities scales suggest a positive trend in the developmental trajectory of general neurocognitive abilities. Some parents reported anxiety and stress but overall they were resilient (and had good coping strategies towards the burden of care for their child. These results reinforce the importance of routinely assessing the neurocognitive aspects in SMA type I patients and to offer an early intervention to favor the psychosocial development of these children. Highlights: Treatments approved for SMA have radically changed the natural history. The neurocognitive profile of treated patients has been poorly explored. We deeply investigated the neurocognitive profile and the emotionalburden of caregivers. Our finding show a global developmental delay. Positive trend of general neurocognitive abilities (language, learning). … (more)
- Is Part Of:
- European journal of paediatric neurology. Volume 43(2023)
- Journal:
- European journal of paediatric neurology
- Issue:
- Volume 43(2023)
- Issue Display:
- Volume 43, Issue 2023 (2023)
- Year:
- 2023
- Volume:
- 43
- Issue:
- 2023
- Issue Sort Value:
- 2023-0043-2023-0000
- Page Start:
- 36
- Page End:
- 43
- Publication Date:
- 2023-03
- Subjects:
- Spinal muscular atrophy -- Cognitive profile -- Resilience -- Parental stress load
Pediatric neurology -- Periodicals
Nervous System Diseases -- Periodicals
Child -- Periodicals
Infant -- Periodicals
Neurologie pédiatrique -- Périodiques
Pediatric neurology
Electronic journals
Periodicals
Electronic journals
618.928 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10903798 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/10903798 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/10903798 ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=1090-3798;screen=info;ECOIP ↗
http://www.elsevier.com/journals ↗
http://www.idealibrary.com/links/toc/ejpn/ ↗
http://www.harcourt-international.com/journals ↗ - DOI:
- 10.1016/j.ejpn.2023.02.004 ↗
- Languages:
- English
- ISSNs:
- 1090-3798
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.733370
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26848.xml